Nacasaki Silvestre Renata, Moço Pablo Diego, Picanço-Castro Virgínia
Center for Cell-Based Therapy CTC, Regional Blood Center of Ribeirão Preto, University of São Paulo, São Paulo, Brazil.
Methods Mol Biol. 2020;2086:213-222. doi: 10.1007/978-1-0716-0146-4_16.
Immunotherapy using T cells modified with chimeric antigen receptor (CAR) has been proven effective in the treatment of leukemia and lymphomas resistant to chemotherapy. Recent clinical studies have shown excellent responses of CAR-T cells in a variety of B cell tumors. However, it is important to validate in vitro activity of these cells, though different sorts of assays, which are capable of measuring the cytotoxic potential of these cells. In this chapter, it will be pointed two methods to evaluate CAR-T cell killing potential against B cell malignancy cell lines.
使用嵌合抗原受体（CAR）修饰的T细胞进行免疫疗法已被证明在治疗对化疗耐药的白血病和淋巴瘤方面有效。最近的临床研究表明，CAR-T细胞在多种B细胞肿瘤中反应良好。然而，通过能够测量这些细胞细胞毒性潜力的不同类型检测来验证这些细胞的体外活性很重要。在本章中，将指出两种评估CAR-T细胞对B细胞恶性肿瘤细胞系杀伤潜力的方法。
